Precision – temporal
Mindpeak Secures First Patent for Advanced AI Method in Digital Pathology
Mindpeak; digital pathology; AI-powered pathology; oncology diagnostics; cell classification; histopathology; EU patent; United Kingdom validation; AI model training; precision diagnostics
BostonGene to Showcase Transformative Impact of AI-Driven Profiling with Six Abstracts at the 67th American Society of Hematology Annual Meeting & Exposition
BostonGene; AI-driven molecular profiling; hematology; 67th ASH Annual Meeting; immune profiling; multiple myeloma; patient stratification; clinical trials; biomarkers; precision oncology
Ratio Therapeutics Appoints Marcel Reichen as Chief Strategy Officer
Ratio Therapeutics; Marcel Reichen; Chief Strategy Officer; radiopharmaceuticals; oncology; radioligand therapy; pharmaceutical industry; cancer treatment; strategic growth; precision oncology
Odyssey Therapeutics Secures $213M Series D to Accelerate Autoimmune Clinical Portfolio
Odyssey Therapeutics; Series D financing; $213 million; autoimmune diseases; clinical pipeline; preclinical programs; precision immunomodulation; RIPK2 inhibitor; PROTAC technology; investors
Exclusive: Merida Biosciences gets $121M to treat autoimmune and allergy diseases at their roots
Autoimmune, Autoimmune Diseases, Precision – temporal
GE HealthCare and UCSF Collaborate on Innovative Imaging Solutions for Cancer and Neurodegenerative Diseases
GE HealthCare, UCSF, Cancer Imaging, Neurodegenerative Disease Imaging, Precision Oncology, Brain Health, Joint Research Program, Care Innovation Hub
GE HealthCare and UCSF Launch ‘Care Innovation Hub’ to Revolutionize Medical Imaging for Cancer and Neurodegenerative Diseases
GE HealthCare, UCSF, Care Innovation Hub, medical imaging, cancer, neurodegenerative diseases, precision oncology, brain health, automated imaging techniques, MRI, radiopharmaceutical therapies.
Light Horse Therapeutics Secures $62M Series A Funding and Partners with Novartis for Cancer Therapies
Light Horse Therapeutics, Novartis, Series A funding, cancer therapies, small molecule therapeutics, precision genetic editing platform
Light Horse Therapeutics Secures $1 Billion+ Novartis Collaboration on Launch Day
Light Horse Therapeutics, Novartis, biotech, strategic collaboration, small molecule therapeutics, precision genome editing, drug discovery
Breakthrough in Graft-Versus-Host Disease Treatment: MaaT013 Microbiome Therapy Shows Unprecedented Efficacy
Graft-Versus-Host Disease (GvHD), Microbiome Therapy, MaaT013, Acute GvHD, Steroid-Resistant GvHD, Faecal Microbiota Transplantation, Precision Nutrition